{"id":"NCT01833494","sponsor":"Kissei Pharmaceutical Co., Ltd.","briefTitle":"A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","officialTitle":"A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-18","primaryCompletion":"2014-08","completion":"2014-08-04","firstPosted":"2013-04-17","resultsPosted":"2018-10-09","lastUpdate":"2018-10-09"},"enrollment":161,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemodialysis Patients With Hyperphosphatemia"],"interventions":[{"type":"DRUG","name":"PA21","otherNames":[]}],"arms":[{"label":"PA21","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to investigate the safety and efficacy for 52-week dosing in hemodialysis patients with hyperphosphatemia.","primaryOutcome":{"measure":"Incidence of Adverse Events","timeFrame":"52 weeks","effectByArm":[{"arm":"PA21","deltaMin":152,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":161},"commonTop":["Nasopharyngitis","Diarrhoea","Contusion","Procedural hypotension","Pain in extremity"]}}